Navigation Links
Controlling Asthma

People with uncontrolled asthma may be able to gain complete control of their condition, say researchers .//

Researchers studied 3,416 patients with uncontrolled asthma. Some of the patients had never before taken an inhaled steroid for their asthma; some were on a low-dose inhaled steroid; and some were on a moderate-dose inhaled steroid. Patients in all three subgroups were randomly assigned to receive either the inhaled steroid fluticasone propionate or a combination of fluticasone propionate and a long-acting beta-2 agonist, salmeterol. All patients were followed for one year.

Researchers defined “total control” of asthma as having no acute attacks, emergency room visits, or adverse drug effects for seven out of eight weeks of assessment. It was observed that 41 percent of the patients achieved total control of their asthma by the one-year follow-up. Many others were considered well controlled. Overall patients taking the combination drug fared the best. The patients also achieved control faster and with lower doses of the inhaled steroid drug.

Thus researchers say that their results demonstrate that in the majority of patients with uncontrolled asthma across a wide range of severities, comprehensive guideline-defined control can be achieved and maintained.
'"/>




Page: 1

Related medicine news :

1. Controlling Asthma during Pregnancy
2. Controlling Allergies Before They Start
3. Controlling High Blood Can Reduce Eye Problems In Diabetics
4. Herb Found To Be Effective In Controlling Blood Sugar Levels
5. Diuretics More Effective In Controlling High Blood Pressure
6. Solution For Controlling The Raising Health Costs
7. Stomach Hormone to Aid in Controlling Appetite
8. Research Identifies Osteoporosis Controlling Protein
9. Researchers Make a Major Strategic Breakthrough in Controlling the AIDS Virus
10. Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers
11. Key Gene Controlling Kidney Development Found
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: